In short
Clinical trials are investigating Hexaminolevulinate in people with non-muscle invasive bladder cancer. These studies look at whether it helps doctors remove bladder tumors more completely and reduce the need for repeat surgery. They mainly focus on safety-related study procedures and how well the surgery works in selected patient groups.
Key points
- Clinical trials of Hexaminolevulinate are studying people with non-muscle invasive bladder cancer. Both trials are Phase 3 and compare a photodynamic diagnosis-guided surgery approach with standard white-light surgery. The main goal is to see whether the tumor is removed more completely and whether fewer patients need repeat surgery. One study looks at residual tumor and new carcinoma in situ at repeat surgery, while the other looks at early cancer recurrence at first follow-up cystoscopy. The studies are authorised and involve selected patient groups with bladder cancer that has not grown into the muscle.
Trial overview
Two authorised Phase 3 clinical trials are studying Hexaminolevulinate in bladder cancer surgery. Both trials focus on non-muscle invasive bladder cancer, which means the cancer has not grown into the muscle layer of the bladder.
These studies compare a photodynamic diagnosis approach during transurethral resection with standard white-light surgery. The main question is whether this approach helps doctors remove more disease and reduce the need for repeat surgery.
Who is being studied
The target population in both trials is people with non-muscle invasive bladder cancer (NMIBC). One trial lists the condition as “Not muscular invasive bladder cancer,” and the other uses the term NMIBC.
These studies are designed for patients who are having bladder tumor surgery and may need a second look operation later. The second trial explains that it is trying to identify patients who could safely avoid an unnecessary repeat resection.
How the trials are designed
Both studies are interventional, which means the research team assigns a treatment strategy and then measures the results. Both are also Phase 3 studies, so they compare the research approach with standard care in larger patient groups.
In NCT06548438, the study compares PDD during TURB with white-light cystoscopy (WLC). The trial includes 300 participants and is focused on the completeness of the first tumor removal.
In 2023-507307-64-00, the study compares a primary PDD-guided TURBT strategy with the standard pathway that includes white-light resection and a repeat resection when needed. This trial includes 258 participants and looks at whether some patients can avoid a second operation.
Main endpoints
The main endpoint in NCT06548438 is the proportion of patients with residual tumor or a new diagnosis of carcinoma in situ at the time of repeat TURB. Residual tumor means cancer still found after the first surgery, and carcinoma in situ means an early flat cancer change in the bladder lining.
The main endpoint in 2023-507307-64-00 is the relative proportion of patients with early bladder cancer recurrence at the first follow-up cystoscopy. Early recurrence is defined differently in the two study arms because the treatment timelines are not the same.
Both trials are therefore measuring how well the surgery removes visible and hidden disease, not just whether the procedure can be done.
What the trials try to show
The first study aims to compare the completeness of TURB with PDD against TURB with white light. It asks whether the PDD-guided approach leaves fewer patients with remaining tumor or upstaging at repeat surgery.
The second study aims to provide strong evidence that a PDD-guided approach may be safe enough to reduce or avoid unnecessary repeat resections in selected NMIBC patients. The brief summary says the investigators want to show that their approach is not oncologically inferior to standard care, meaning it should not be worse for cancer control.
These studies are important because they focus on a practical question in bladder cancer care: whether better imaging during surgery can improve treatment and possibly reduce extra procedures.
Key patient terms
- TURBT is surgery through the urethra to remove a bladder tumor.
- Repeat resection means a second surgery after the first tumor removal to check for leftover disease.
- Follow-up cystoscopy is a later bladder check with a camera to look for cancer coming back.
- Standard of care means the usual treatment doctors already use in regular practice.
- Oncologically inferior means worse for cancer control, which the second trial aims to rule out.